• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Liz Hollis

Liz Hollis

Articles

ARTICLES

FDA grants breakthrough designation to Foundation for liquid biopsy assay

April 27, 2018
By Liz Hollis
A liquid biopsy assay that incorporates multiple companion diagnostics has gotten a boost from the FDA. Cambridge, Mass.-based Foundation Medicine Inc. reported that the agency had granted a breakthrough device designation for an expanded version of its FoundationACT (Assay for Circulating Tumor DNA) assay, which would include more than 70 genes and genomic biomarkers for microsatellite instability and blood tumor mutational burden.
Read More

Boston Scientific lifts revenue guidance as numbers beat Wall Street consensus

April 26, 2018
By Liz Hollis
Boston Scientific Corp. (NYSE:BSX) was on the rise Wednesday after posting first-quarter results that beat expectations. The Marlborough, Mass.-based company also reported that it was raising its 2018 revenue guidance range to $9.75 billion to $9.9 billion, up from a predicted $9.65 billion to $9.8 billion. The company closed at $29.42 after opening at $28.35.
Read More

Boston Scientific highlights positive one-year data with Vercise system

April 25, 2018
By Liz Hollis
A day ahead of its first-quarter earnings call, Boston Scientific Corp. touted one-year data from the INTREPID study, which evaluated its Vercise direct brain stimulation (DBS) system to treat the symptoms of Parkinson's disease. Among the data highlights was an overall sustained improvement in quality of life.
Read More

Proton Partners, Sweden's Elekta ink $35M deal for MR-linac systems

April 24, 2018
By Liz Hollis
As it works to ramp up its U.K.-based oncology centers, Proton Partners International Ltd. has agreed to buy magnetic resonance (MR)-linac systems from Stockholm-based Elekta. The order is valued at £25 million (US$34.9 million), with the agreement
Read More

Qiagen eyes new markets after test approved to predict spontaneous preterm birth

April 23, 2018
By Liz Hollis

Sientra looks to regain market share following approval of PMA supplement

April 20, 2018
By Liz Hollis
Santa Barbara, Calif.-based Sientra Inc. (NASDAQ: SIEN) scored a big win this week, with the company reporting after the market closed Wednesday that the FDA had approved a final process enhancement for a manufacturing facility. As a result, Sientra is poising to regain market share with its Opus-branded breast implant products and ending an ordeal spawned by an inspection of a contract manufacturer in Brazil. Sientra closed at $11.98 Thursday after closing at $11.05 the previous day.
Read More

Cybersecurity, integration of CDRH offices take center stage in FDA's new safety plan

April 19, 2018
By Liz Hollis
Establishing a more modern 510(k) pathway, proposing a postmarket authority related to the disclosure of cyber-vulnerabilities, and improving the quality of real-world evidence generation for technologies that address women's health are three proposals the FDA has put forward as it looks to enhance the safety of medical devices throughout the total product lifecycle (TPLC).
Read More

Livanova gets CE mark for VNS therapy system

April 18, 2018
By Liz Hollis

Eyeing PMA, Intact Vascular scoops up $20M in series C

April 17, 2018
By Liz Hollis

Manufacturing issue leads to hold on Endologix endovascular AAA system

Dec. 28, 2016
By Liz Hollis
With 2016 wrapping up, Irvine, Calif.-based Endologix Inc., is facing another challenge in the form of a temporary hold on shipments of its AFX endovascular abdominal aortic aneurysm system due to a manufacturing problem. The hold comes shortly after the company had its CE mark for AFX suspended, as well as the receipt of an FDA request for two-year patient follow-up data for the Nellix endovascular aneurysm sealing system.
Read More
View All Articles by Liz Hollis

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe